Skip to main content
Top
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Tramadol | Research

Comparative safety of tramadol and other opioids following total hip and knee arthroplasty

Authors: Elliott Bosco, Melissa R. Riester, Francesca L. Beaudoin, Andrew J. Schoenfeld, Stefan Gravenstein, Vincent Mor, Andrew R. Zullo

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Tramadol is increasingly used to treat acute postoperative pain among older adults following total hip and knee arthroplasty (THA/TKA). However, tramadol has a complex pharmacology and may be no safer than full opioid agonists. We compared the safety of tramadol, oxycodone, and hydrocodone among opioid-naïve older adults following elective THA/TKA.

Methods

This retrospective cohort included Medicare Fee-for-Service beneficiaries ≥ 65 years with elective THA/TKA between January 1, 2010 and September 30, 2015, 12 months of continuous Parts A and B enrollment, 6 months of continuous Part D enrollment, and no opioid use in the 6 months prior to THA/TKA. Participants initiated single-opioid therapy with tramadol, oxycodone, or hydrocodone within 7 days of discharge from THA/TKA hospitalization, regardless of concurrently administered nonopioid analgesics. Outcomes of interest included all-cause hospitalizations or emergency department visits (serious adverse events (SAEs)) and a composite of 10 surgical- and opioid-related SAEs within 90-days of THA/TKA. The intention-to-treat (ITT) and per-protocol (PP) hazard ratios (HRs) for tramadol versus other opioids were estimated using inverse-probability-of-treatment-weighted pooled logistic regression models.

Results

The study population included 2,697 tramadol, 11,407 oxycodone, and 14,665 hydrocodone initiators. Compared to oxycodone, tramadol increased the rate of all-cause SAEs in ITT analyses only (ITT HR 1.19, 95%CLs, 1.02, 1.41; PP HR 1.05, 95%CLs, 0.86, 1.29). Rates of composite SAEs were not significant across comparisons. Compared to hydrocodone, tramadol increased the rate of all-cause SAEs in the ITT and PP analyses (ITT HR 1.40, 95%CLs, 1.10, 1.76; PP HR 1.34, 95%CLs, 1.03, 1.75), but rates of composite SAEs were not significant across comparisons.

Conclusions

Postoperative tramadol was associated with increased rates of all-cause SAEs, but not composite SAEs, compared to oxycodone and hydrocodone. Tramadol does not appear to have a superior safety profile and should not be preferentially prescribed to opioid-naïve older adults following THA/TKA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wainwright TW, Gill M, McDonald DA, Middleton RG, Reed M, Sahota O, et al. Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations. Acta Orthop. 2020;91(1):3–19.PubMedCrossRef Wainwright TW, Gill M, McDonald DA, Middleton RG, Reed M, Sahota O, et al. Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations. Acta Orthop. 2020;91(1):3–19.PubMedCrossRef
2.
go back to reference Webster L, Rauck RL. Atypical opioids and their effect on respiratory drive. J Opioid Manag. 2021;17(7):109–18.PubMedCrossRef Webster L, Rauck RL. Atypical opioids and their effect on respiratory drive. J Opioid Manag. 2021;17(7):109–18.PubMedCrossRef
3.
go back to reference Bono JV, Robbins CE, Mehio AK, Aghazadeh M, Talmo CT. Pharmacologic pain management before and after total joint replacement of the hip and knee. Clin Geriatr Med. 2012;28(3):459–70.PubMedCrossRef Bono JV, Robbins CE, Mehio AK, Aghazadeh M, Talmo CT. Pharmacologic pain management before and after total joint replacement of the hip and knee. Clin Geriatr Med. 2012;28(3):459–70.PubMedCrossRef
4.
go back to reference Wang Y, Wu D, Chan A, Chang CH, Lee VWY, Nichol MB. Temporal trend of opioid and nonopioid pain medications: results from a national in-home survey, 2001 to 2018. Pain Rep. 2022;7(3):e1010.PubMedPubMedCentralCrossRef Wang Y, Wu D, Chan A, Chang CH, Lee VWY, Nichol MB. Temporal trend of opioid and nonopioid pain medications: results from a national in-home survey, 2001 to 2018. Pain Rep. 2022;7(3):e1010.PubMedPubMedCentralCrossRef
5.
go back to reference Bigal LM, Bibeau K, Dunbar S. Tramadol Prescription over a 4-Year Period in the USA. Curr Pain Headache Rep. 2019;23(10):76.PubMedCrossRef Bigal LM, Bibeau K, Dunbar S. Tramadol Prescription over a 4-Year Period in the USA. Curr Pain Headache Rep. 2019;23(10):76.PubMedCrossRef
6.
go back to reference DeMik DE, Carender CN, Shamrock AG, Callaghan JJ, Bedard NA. Opioid Use After Total Knee Arthroplasty: Does Tramadol Have Lower Risk Than Traditional Opioids? J Arthroplasty. 2020;35(6):1558–62.PubMedCrossRef DeMik DE, Carender CN, Shamrock AG, Callaghan JJ, Bedard NA. Opioid Use After Total Knee Arthroplasty: Does Tramadol Have Lower Risk Than Traditional Opioids? J Arthroplasty. 2020;35(6):1558–62.PubMedCrossRef
7.
go back to reference Mullins PM, Mazer-Amirshahi M, Pourmand A, Perrone J, Nelson LS, Pines JM. Tramadol Use in United States Emergency Departments 2007–2018. J Emerg Med. 2022;62(5):668–74.PubMedCrossRef Mullins PM, Mazer-Amirshahi M, Pourmand A, Perrone J, Nelson LS, Pines JM. Tramadol Use in United States Emergency Departments 2007–2018. J Emerg Med. 2022;62(5):668–74.PubMedCrossRef
8.
go back to reference McCartney CJL, Nelligan K. Postoperative pain management after total knee arthroplasty in elderly patients: treatment options. Drugs Aging. 2014;31(2):83–91.PubMedCrossRef McCartney CJL, Nelligan K. Postoperative pain management after total knee arthroplasty in elderly patients: treatment options. Drugs Aging. 2014;31(2):83–91.PubMedCrossRef
9.
go back to reference Hannon CP, Fillingham YA, Nam D, Courtney PM, Curtin BM, Vigdorchik J, et al. The Efficacy and Safety of Opioids in Total Joint Arthroplasty: Systematic Review and Direct Meta-Analysis. J Arthroplasty. 2020;35(10):2759-71.e13.PubMedCrossRef Hannon CP, Fillingham YA, Nam D, Courtney PM, Curtin BM, Vigdorchik J, et al. The Efficacy and Safety of Opioids in Total Joint Arthroplasty: Systematic Review and Direct Meta-Analysis. J Arthroplasty. 2020;35(10):2759-71.e13.PubMedCrossRef
10.
go back to reference Intrator O, Hiris J, Berg K, Miller SC, Mor V. The residential history file: studying nursing home residents’ long-term care histories(*). Health Serv Res. 2011;46(1 Pt 1):120–37.PubMedPubMedCentralCrossRef Intrator O, Hiris J, Berg K, Miller SC, Mor V. The residential history file: studying nursing home residents’ long-term care histories(*). Health Serv Res. 2011;46(1 Pt 1):120–37.PubMedPubMedCentralCrossRef
12.
13.
go back to reference Jeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, et al. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use. Ann Emerg Med. 2018;71(3):326-36.e19.PubMedCrossRef Jeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, et al. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use. Ann Emerg Med. 2018;71(3):326-36.e19.PubMedCrossRef
14.
go back to reference Savitz ST, Stearns SC, Groves JS, Kucharska-Newton AM, Bengtson LGS, Wruck L. Mind the Gap: Hospitalizations from Multiple Sources in a Longitudinal Study. Value in health. 2017;20(6):777–84.PubMedCrossRef Savitz ST, Stearns SC, Groves JS, Kucharska-Newton AM, Bengtson LGS, Wruck L. Mind the Gap: Hospitalizations from Multiple Sources in a Longitudinal Study. Value in health. 2017;20(6):777–84.PubMedCrossRef
15.
go back to reference Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, et al. Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction. JAMA Intern Med. 2017;177(2):254–62.PubMedPubMedCentralCrossRef Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, et al. Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction. JAMA Intern Med. 2017;177(2):254–62.PubMedPubMedCentralCrossRef
16.
go back to reference Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran’s affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007;60(4):397–409.PubMedCrossRef Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran’s affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007;60(4):397–409.PubMedCrossRef
17.
go back to reference Olsen MA, Ball KE, Nickel KB, Wallace AE, Fraser VJ. Validation of ICD-9-CM Diagnosis Codes for Surgical Site Infection and Noninfectious Wound Complications After Mastectomy. Infect Control Hosp Epidemiol. 2017;38(3):334–9.PubMedCrossRef Olsen MA, Ball KE, Nickel KB, Wallace AE, Fraser VJ. Validation of ICD-9-CM Diagnosis Codes for Surgical Site Infection and Noninfectious Wound Complications After Mastectomy. Infect Control Hosp Epidemiol. 2017;38(3):334–9.PubMedCrossRef
18.
go back to reference Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, et al. Validation of acute myocardial infarction in the Food and Drug Administration’s Mini-Sentinel program. Pharmacoepidemiol Drug Saf. 2013;22(1):40–54.PubMedCrossRef Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, et al. Validation of acute myocardial infarction in the Food and Drug Administration’s Mini-Sentinel program. Pharmacoepidemiol Drug Saf. 2013;22(1):40–54.PubMedCrossRef
19.
go back to reference Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7(4):611–9.PubMedPubMedCentralCrossRef Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7(4):611–9.PubMedPubMedCentralCrossRef
20.
go back to reference Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):129–40.PubMedCrossRef Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):129–40.PubMedCrossRef
21.
go back to reference Singh S, Fouayzi H, Anzuoni K, Goldman L, Min JY, Griffin M, et al. Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. Drug Saf. 2019;42(4):515–27.PubMedCrossRef Singh S, Fouayzi H, Anzuoni K, Goldman L, Min JY, Griffin M, et al. Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. Drug Saf. 2019;42(4):515–27.PubMedCrossRef
22.
go back to reference Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG. Identification and validation of vertebral compression fractures using administrative claims data. Med Care. 2009;47(1):69–72.PubMedPubMedCentralCrossRef Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG. Identification and validation of vertebral compression fractures using administrative claims data. Med Care. 2009;47(1):69–72.PubMedPubMedCentralCrossRef
23.
go back to reference Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992;45(7):703–14.PubMedCrossRef Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992;45(7):703–14.PubMedCrossRef
24.
go back to reference Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133(3):790–8.PubMedCrossRef Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133(3):790–8.PubMedCrossRef
25.
go back to reference Abraham NS, Cohen DC, Rivers B, Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther. 2006;24(2):299–306.PubMedCrossRef Abraham NS, Cohen DC, Rivers B, Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther. 2006;24(2):299–306.PubMedCrossRef
26.
go back to reference Winner M, Mooney SJ, Hershman DL, Feingold DL, Allendorf JD, Wright JD, et al. Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. JAMA Surg. 2013;148(8):715–22.PubMedPubMedCentralCrossRef Winner M, Mooney SJ, Hershman DL, Feingold DL, Allendorf JD, Wright JD, et al. Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. JAMA Surg. 2013;148(8):715–22.PubMedPubMedCentralCrossRef
27.
go back to reference Lo ReHaynesGoldbergFordeCarbonariLeidl VKDKADMKB 3rd, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861–72.CrossRef Lo ReHaynesGoldbergFordeCarbonariLeidl VKDKADMKB 3rd, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861–72.CrossRef
28.
go back to reference Waikar SS, Wald R, Chertow GM, Curhan GC, Winkelmayer WC, Liangos O, et al. Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol. 2006;17(6):1688–94.PubMedCrossRef Waikar SS, Wald R, Chertow GM, Curhan GC, Winkelmayer WC, Liangos O, et al. Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol. 2006;17(6):1688–94.PubMedCrossRef
29.
go back to reference Heslin KC, Owens PL, Karaca Z, Barrett ML, Moore BJ, Elixhauser A. Trends in Opioid-related Inpatient Stays Shifted After the US Transitioned to ICD-10-CM Diagnosis Coding in 2015. Med Care. 2017;55(11):918–23.PubMedCrossRef Heslin KC, Owens PL, Karaca Z, Barrett ML, Moore BJ, Elixhauser A. Trends in Opioid-related Inpatient Stays Shifted After the US Transitioned to ICD-10-CM Diagnosis Coding in 2015. Med Care. 2017;55(11):918–23.PubMedCrossRef
30.
go back to reference Kim DH, Lee J, Kim CA, Huybrechts KF, Bateman BT, Patorno E, et al. Evaluation of algorithms to identify delirium in administrative claims and drug utilization database. Pharmacoepidemiol Drug Saf. 2017;26(8):945–53.PubMedPubMedCentralCrossRef Kim DH, Lee J, Kim CA, Huybrechts KF, Bateman BT, Patorno E, et al. Evaluation of algorithms to identify delirium in administrative claims and drug utilization database. Pharmacoepidemiol Drug Saf. 2017;26(8):945–53.PubMedPubMedCentralCrossRef
31.
go back to reference Jones N, Schneider G, Kachroo S, Rotella P, Avetisyan R, Reynolds MW. A systematic review of validated methods for identifying acute respiratory failure using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):261–4.PubMedCrossRef Jones N, Schneider G, Kachroo S, Rotella P, Avetisyan R, Reynolds MW. A systematic review of validated methods for identifying acute respiratory failure using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):261–4.PubMedCrossRef
32.
go back to reference Eicheldinger C, Bonito A. More accurate racial and ethnic codes for Medicare administrative data. Health Care Financ Rev. 2008;29(3):27–42.PubMedPubMedCentral Eicheldinger C, Bonito A. More accurate racial and ethnic codes for Medicare administrative data. Health Care Financ Rev. 2008;29(3):27–42.PubMedPubMedCentral
33.
go back to reference Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.PubMedPubMedCentralCrossRef Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.PubMedPubMedCentralCrossRef
34.
go back to reference Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2018;73(7):980–7.PubMedCrossRef Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2018;73(7):980–7.PubMedCrossRef
35.
go back to reference Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J, et al. Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. Arthritis & Rheumatology. 2019;71(5):712–21.CrossRef Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J, et al. Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. Arthritis & Rheumatology. 2019;71(5):712–21.CrossRef
36.
go back to reference Hernan MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. N Engl J Med. 2017;377(14):1391–8.PubMedCrossRef Hernan MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. N Engl J Med. 2017;377(14):1391–8.PubMedCrossRef
37.
go back to reference McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388–414.PubMedPubMedCentralCrossRef McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388–414.PubMedPubMedCentralCrossRef
38.
go back to reference Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399–424.CrossRef Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399–424.CrossRef
39.
go back to reference Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367: l5657.PubMedCrossRef Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367: l5657.PubMedCrossRef
40.
go back to reference Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45–9.PubMedCrossRef Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45–9.PubMedCrossRef
41.
go back to reference Altman DG. Confidence intervals for the number needed to treat. BMJ (Clinical research ed). 1998;317(7168):1309–12.PubMedCrossRef Altman DG. Confidence intervals for the number needed to treat. BMJ (Clinical research ed). 1998;317(7168):1309–12.PubMedCrossRef
42.
go back to reference VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268–74.PubMedCrossRef VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268–74.PubMedCrossRef
43.
44.
go back to reference Hannon CP, Fillingham YA, Nam D, Courtney PM, Curtin BM, Vigdorchik JM, et al. Opioids in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. J Arthroplasty. 2020;35(10):2709–14.PubMedCrossRef Hannon CP, Fillingham YA, Nam D, Courtney PM, Curtin BM, Vigdorchik JM, et al. Opioids in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. J Arthroplasty. 2020;35(10):2709–14.PubMedCrossRef
45.
go back to reference Stubhaug A, Grimstad J, Breivik H. Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain. 1995;62(1):111–8.PubMedCrossRef Stubhaug A, Grimstad J, Breivik H. Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain. 1995;62(1):111–8.PubMedCrossRef
46.
go back to reference Kleeman-Forsthuber L, Pollet A, Johnson RM, Boyle J, Jennings JM, Dennis DA. Evaluation of Low-Dose Versus High-Dose Opioid Pathway in Opioid-Naive Patients After Total Knee Arthroplasty. Arthroplast Today. 2022;14:81–5.PubMedPubMedCentralCrossRef Kleeman-Forsthuber L, Pollet A, Johnson RM, Boyle J, Jennings JM, Dennis DA. Evaluation of Low-Dose Versus High-Dose Opioid Pathway in Opioid-Naive Patients After Total Knee Arthroplasty. Arthroplast Today. 2022;14:81–5.PubMedPubMedCentralCrossRef
47.
go back to reference Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979–86.PubMedCrossRef Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979–86.PubMedCrossRef
48.
go back to reference Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–76.PubMedCrossRef Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–76.PubMedCrossRef
49.
go back to reference Zeng C, Dubreuil M, LaRochelle MR, Lu N, Wei J, Choi HK, et al. Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis. JAMA. 2019;321(10):969–82.PubMedPubMedCentralCrossRef Zeng C, Dubreuil M, LaRochelle MR, Lu N, Wei J, Choi HK, et al. Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis. JAMA. 2019;321(10):969–82.PubMedPubMedCentralCrossRef
50.
go back to reference Wei J, Lane NE, Bolster MB, Dubreuil M, Zeng C, Misra D, et al. Association of Tramadol Use With Risk of Hip Fracture. J Bone Miner Res. 2020;35(4):631–40.PubMedCrossRef Wei J, Lane NE, Bolster MB, Dubreuil M, Zeng C, Misra D, et al. Association of Tramadol Use With Risk of Hip Fracture. J Bone Miner Res. 2020;35(4):631–40.PubMedCrossRef
51.
go back to reference Musich S, Wang SS, Schaeffer JA, Slindee L, Kraemer S, Yeh CS. Safety Events Associated with Tramadol Use Among Older Adults with Osteoarthritis. Popul Health Manag. 2021;24(1):122–32.PubMedPubMedCentralCrossRef Musich S, Wang SS, Schaeffer JA, Slindee L, Kraemer S, Yeh CS. Safety Events Associated with Tramadol Use Among Older Adults with Osteoarthritis. Popul Health Manag. 2021;24(1):122–32.PubMedPubMedCentralCrossRef
52.
go back to reference Rosenthal NR, Silverfield JC, Wu SC, Jordan D, Kamin M. Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc. 2004;52(3):374–80.PubMedCrossRef Rosenthal NR, Silverfield JC, Wu SC, Jordan D, Kamin M. Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc. 2004;52(3):374–80.PubMedCrossRef
53.
go back to reference Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28(1):59–71.PubMedCrossRef Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28(1):59–71.PubMedCrossRef
54.
go back to reference Aweid O, Haider Z, Saed A, Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: A systematic review of safety. J Orthop Surg (Hong Kong). 2018;26(3):2309499018808669.PubMedCrossRef Aweid O, Haider Z, Saed A, Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: A systematic review of safety. J Orthop Surg (Hong Kong). 2018;26(3):2309499018808669.PubMedCrossRef
55.
go back to reference Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution–a simulation study. Am J Epidemiol. 2010;172(7):843–54.PubMedPubMedCentralCrossRef Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution–a simulation study. Am J Epidemiol. 2010;172(7):843–54.PubMedPubMedCentralCrossRef
57.
go back to reference Zullo AR, Danko KJ, Moyo P, Adam GP, Riester M, Kimmel MJ, et al. HRQ Comparative Effectiveness Technical Briefs. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.CrossRef Zullo AR, Danko KJ, Moyo P, Adam GP, Riester M, Kimmel MJ, et al. HRQ Comparative Effectiveness Technical Briefs. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.CrossRef
Metadata
Title
Comparative safety of tramadol and other opioids following total hip and knee arthroplasty
Authors
Elliott Bosco
Melissa R. Riester
Francesca L. Beaudoin
Andrew J. Schoenfeld
Stefan Gravenstein
Vincent Mor
Andrew R. Zullo
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-04933-2

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine